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Background: Ileus is common after elective colorectal surgery, and is associated with increased adverse
events and prolonged hospital stay. The aim was to assess the role of non-steroidal anti-inflammatory
drugs (NSAIDs) for reducing ileus after surgery.
Methods: A prospective multicentre cohort study was delivered by an international, student- and
trainee-led collaborative group. Adult patients undergoing elective colorectal resection between January
and April 2018 were included. The primary outcome was time to gastrointestinal recovery, measured
using a composite measure of bowel function and tolerance to oral intake. The impact of NSAIDs was
explored using Cox regression analyses, including the results of a centre-specific survey of compliance
to enhanced recovery principles. Secondary safety outcomes included anastomotic leak rate and acute
kidney injury.
Results: A total of 4164 patients were included, with a median age of 68 (i.q.r. 57–75) years (54⋅9 per
cent men). Some 1153 (27⋅7 per cent) received NSAIDs on postoperative days 1–3, of whom 1061 (92⋅0
per cent) received non-selective cyclo-oxygenase inhibitors. After adjustment for baseline differences, the
mean time to gastrointestinal recovery did not differ significantly between patients who received NSAIDs
and those who did not (4⋅6 versus 4⋅8 days; hazard ratio 1⋅04, 95 per cent c.i. 0⋅96 to 1⋅12; P =0⋅360). There
were no significant differences in anastomotic leak rate (5⋅4 versus 4⋅6 per cent; P = 0⋅349) or acute kidney
injury (14⋅3 versus 13⋅8 per cent; P = 0⋅666) between the groups. Significantly fewer patients receiving
NSAIDs required strong opioid analgesia (35⋅3 versus 56⋅7 per cent; P <0⋅001).
Conclusion: NSAIDs did not reduce the time for gastrointestinal recovery after colorectal surgery, but
they were safe and associated with reduced postoperative opioid requirement.
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Introduction
Ileus is common after colorectal surgery. It occurs in 10–20
per cent of patients after elective colonic resection, mak-
ing it the most common complication ahead of anastomotic
leak and surgical-site infection1. In 2014, the Association
of Coloproctology in Great Britain and Ireland2 identified
ileus as an unmet clinical challenge. Its clinical manifes-
tations are profound, contributing to postoperative pain,
vomiting and malnutrition. Its burden on healthcare sys-
tems is also substantial, leading to a 70 per cent increase in
healthcare costs3.
Many strategies to reduce ileus have been tested in
the past 20 years, but few have resulted in meaningful
clinical benefits4. This may be attributed to an incom-
plete understanding of the pathophysiology, and differ-
ences between experimental animal models and humans5.
Current evidence describes a complex relationship between
inflammatory, neurogenic and vagal mechanisms, which
are exacerbated by the effects of opioid analgesia and
other homeostatic imbalances6. To date, the most promis-
ing strategies have been those that aim to rationalize
opioid-based analgesia (such as μ-receptor antagonists),
and to moderate the postoperative inflammatory response
(such as enhanced recovery protocols)4.
Non-steroidal anti-inflammatory drugs (NSAIDs) are
recommended in enhanced recovery protocols for their
opioid-sparing and anti-inflammatory properties7. These
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may have benefits for the recovery of gastrointestinal func-
tion. Recent meta-analyses8,9 of RCTs demonstrated a sig-
nificant pooled benefit of NSAIDs in reducing ileus after
colorectal surgery. However, the use of NSAIDs in this
setting is controversial owing to the risk of acute kid-
ney injury and conflicting reports of increased anasto-
motic leak rates10,11. NSAIDs may represent a simple and
cost-effective intervention to reduce ileus.
The primary aim of this study was to explore the relation-
ship between NSAIDs and the recovery of gastrointestinal
function (resolution of ileus) after colorectal surgery. It also
aimed to examine key safety outcomes, when NSAIDs are
administered in the early postoperative phase.
Methods
The study protocol was developed by an international man-
agement group, with input from patient representatives.
The protocol was registered prospectively at the Research
Registry Service (https://www.researchregistry.com) (UIN
3072) and published before the study started12. Study
approvals and requirements for individual patient consent
were satisfied according to country-specific regulations.
This manuscript is the first analysis of the international
IMAGINE study and is reported in line with the STROBE
statement13.
Study design
A prospective multicentre observational study was deliv-
ered by a student- and trainee-led collaborative group with
a track record of international research14. The study design
was informed by an external pilot study in a comparable
patient cohort in the UK15. A 17-item, prestudy survey of
compliance to enhanced recovery principles was completed
by representatives of participating hospitals before the start
of data collection (Table S1, supporting information) and
used to produce a score (enhanced recovery after surgery
(ERAS) score). To determine the accuracy and complete-
ness of data, an independent validation exercise was pre-
planned in at least 10 per cent of centres. This comprised
two domains; the first was data accuracy, determined by
assessing the accuracy of ten planned data points; the sec-
ond was case ascertainment, determined by assessing the
accuracy of participant eligibility. No change to the final
data set was planned based on this exercise, but an accu-
racy of at least 95 per cent in each domain was considered
sufficient for validation.
Study setting
Hospitals performing elective colorectal surgery in
Europe, Australasia and South Africa were eligible to
enrol in the study. Each hospital enrolled consecutive
patients in up to three 14-day data collection intervals
between January and April 2018.
Eligibility criteria
Adult patients having elective colorectal resection via open,
laparoscopic or robotic approaches for any indication
(malignant or benign) were eligible. Procedures performed
via a transanal approach, and those for primary gynae-
cological, hepatobiliary, urological or vascular pathologies
were excluded. Return to theatre was considered to repre-
sent an acute episode and was not eligible. Elective appen-
dicectomy was excluded, unless a more extensive colorectal
resection was undertaken. Patients undergoing restoration
of intestinal continuity were included, but will be reported
elsewhere12.
Outcome measures
The primary outcome was time to gastrointestinal recov-
ery. The validated GI-2 composite measure was used,
defined as the time taken for patients to tolerate solid
food and to pass stool16. This included soft food, but
not liquids. Secondary outcomes were postoperative
complications occurring within 30 days of surgery. The
Clavien–Dindo system17 was used to classify each patient’s
most severe encountered complication: no complication
(grade 0), minor complication (grades I–II) or major com-
plication (grades III–V). Anastomotic leak was defined as
bowel leakage detected radiologically, or at the time of
reoperation. Acute kidney injury was defined according to
the Kidney Disease Improving Global Outcomes serum
creatinine-based criteria18.
Explanatory variables
The main variable of interest was early administration
of NSAIDs after surgery. Patients were considered to
have received a course of NSAIDs if received on at least
2 days (at least 1 dose per day) within the first 3 days after
operation. Variables including ASA fitness grade, BMI
and smoking status were collected for risk adjustment.
Other variables of interest were those known to affect
gastrointestinal recovery after surgery: cardiovascular and
metabolic diseases (chronic obstructive pulmonary dis-
ease, ischaemic heart disease, peripheral artery disease and
diabetes mellitus), previous abdominal surgery, operative
approach, transfusion of red cells, postoperative adminis-
tration of strong opioids (defined as at least 2 days of oral
or parenteral treatment within the first 3 days after surgery)
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and centre-specific compliance with enhanced recovery
principles19. Examples of strong and weak opioids rele-
vant to this study are provided in Table S2 (supporting
information).
Statistical analysis
A detailed statistical analysis plan and power calculation has
been published previously12. The study was powered based
on a comparison of GI-2 between patients who received
NSAIDs and those who did not. Based on data from an
external pilot study, it was estimated that it would be feasi-
ble to recruit approximately 3500 participants during the
study interval, and that the NSAID administration rate
would be approximately 15 per cent20. A power calcula-
tion assuming these values returned a minimal detectable
difference in GI-2 of 0⋅2 days between groups (5 per cent
α; 80 per cent power). A difference in GI-2 of 1 day was
considered clinically meaningful when applied to real prac-
tice, so the study was adequately powered for this clinical
difference.
Patient demographics, perioperative variables and safety
outcomes were compared between treatment groups using
the χ2 test for nominal variables, and Mann–Whitney U
test for ordinal or continuous variables.
A Cox regression model was used for univariable analy-
sis, with the differences across treatment groups quantified
using Kaplan–Meier curves and mean times to GI-2. Mul-
tivariable Cox regression models were then produced to
identify independent predictors of the time to GI-2. The
maximum follow-up was 10 days; patients were censored
at this point if GI-2 had not been achieved. As achieving
GI-2 was treated as the event in the analyses, a hazard
ratio (HR) greater than 1⋅00 was indicative of a greater
hazard of achieving GI-2 and, accordingly, a shorter time
to GI-2.
In the main analysis, patients were censored at discharge
or death in hospital, as the time to GI-2 was not known
for these patients. However, this may have violated the
assumption of non-informative censoring. Patients who
were discharged would have been deemed fit at this point,
and would probably have achieved GI-2 soon after. In
the case of inpatient death, the patient would have had
no opportunity to achieve GI-2, even if follow-up had
been extended indefinitely. As such, a sensitivity analysis
was undertaken that treated patients discharged before
achieving GI-2 as having achieved GI-2 on the day of
discharge. Those who died in hospital before achieving
GI-2 were treated as not having achieved GI-2 by day 10,
rather than being censored at the point of death in this
sensitivity analysis.
A multivariable analysis of safety outcomes was carried
out to assess whether any of these were associated inde-
pendently with NSAID use. Duration of hospital stay was
highly skewed, so was dichotomized for analysis, based on
the median value. All outcomes were analysed using mul-
tivariable binary logistic regression models. The NSAID
group was entered into each model as a predictor, with a
backwards stepwise approach used to select other preoper-
ative and perioperative factors that were associated inde-
pendently with the outcome being considered.
P < 0⋅050 was deemed to be indicative of statistical sig-
nificance throughout. All analyses were performed using
SPSS® version 22 (IBM, Armonk, New York, USA).
Results
Data were available for 4164 patients, with a median age of
68 (i.q.r. 57–75) years, of whom 54⋅9 per cent were men.
An anastomosis was constructed in 3638 patients (87⋅4 per
cent). Between postoperative days 1 and 3, 1153 patients
(27⋅7 per cent) received an early course of NSAIDs:
non-selective cyclo-oxygenase (COX) inhibitors in 1061
patients (92⋅0 per cent) and COX-2-selective agents in 92
(8⋅0 per cent). Data validation was performed using infor-
mation on 892 patients from 111 centres (21⋅4 per cent
sample of the total cohort), with 95⋅9 per cent data accuracy
and 99⋅7 per cent case ascertainment.
Baseline data
Some differences in baseline patient variables were
observed between treatment groups (Table 1). Patients
receiving NSAIDs were significantly younger (median
66 versus 68 years; P < 0⋅001), more likely to be smokers
(17⋅9 versus 15⋅2 per cent; P = 0⋅033) and had lower ASA
grades (P = 0⋅040) and ERAS scores (P < 0⋅001) than those
not treated with NSAIDs. A significant difference in sur-
gical pathology was also identified (P = 0⋅013); NSAIDs
were used more frequently among patients treated for
malignancy.
Operative and postoperative treatment
There were also differences in operative and postopera-
tive factors between treatment groups (Table 2). Patients
receiving NSAIDs were more likely to have had open
surgery (40⋅3 versus 35⋅6 per cent; P = 0⋅001) and to have
undergone a left colonic resection (25⋅0 versus 21⋅7 per
cent; P = 0⋅024). Where C-reactive protein (CRP) levels
were recorded between postoperative days 1 and 3, these
were significantly lower in patients treated with NSAIDs
(median 100 versus 118 mg/l; P < 0⋅001). Patients receiving
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Table 1 Baseline data by non-steroidal anti-inflammatory drug use
NSAID use
No. of patients No Yes P†
Age (years)* 4162 68 (57–75) 66 (55–74) <0⋅001‡
Men 4164 1654 (54⋅9) 634 (55⋅0) 1⋅000
BMI (kg/m2) 4159 0⋅050‡§
<18⋅5 79 (2⋅6) 37 (3⋅2)
18⋅5–24⋅9 1168 (38⋅8) 476 (41⋅4)
25⋅0–30⋅0 1135 (37⋅7) 419 (36⋅4)
>30⋅0 626 (20⋅8) 219 (19⋅0)
Current smoker 4155 455 (15⋅2) 206 (17⋅9) 0⋅033
ASA fitness grade 4160 0⋅040‡§
I 320 (10⋅6) 147 (12⋅8)
II 1700 (56⋅5) 656 (56⋅9)
III 904 (30⋅1) 318 (27⋅6)
IV–V 84 (2⋅8) 31 (2⋅7)
Previous abdominal surgery 4163 1206 (40⋅1) 497 (43⋅1) 0⋅078
Existing stoma 4163 0⋅351
No 2784 (92⋅5) 1079 (93⋅6)
Ileostomy 116 (3⋅9) 42 (3⋅6)
Colostomy 110 (3⋅7) 32 (2⋅8)
History of IHD 4164 361 (12⋅0) 131 (11⋅4) 0⋅592
History of PAD 4164 177 (5⋅9) 82 (7⋅1) 0⋅151
History of COPD 4164 214 (7⋅1) 76 (6⋅6) 0⋅587
History of diabetes 4164 0⋅082
No 2528 (84⋅0) 960 (83⋅3)
Diet/tablet-controlled 387 (12⋅9) 140 (12⋅1)
Insulin-controlled 96 (3⋅2) 53 (4⋅6)
ERAS score 4164 <0⋅001‡§
<12 564 (18⋅7) 367 (31⋅8)
12–13 718 (23⋅8) 274 (23⋅8)
14–15 725 (24⋅1) 275 (23⋅9)
≥16 1004 (33⋅3) 237 (20⋅6)
Underlying pathology 4164 0⋅013
Diverticular disease 160 (5⋅3) 79 (6⋅9)
Inflammatory bowel disease 309 (10⋅3) 91 (7⋅9)
Malignancy 2354 (78⋅2) 925 (80⋅2)
Other benign disease 188 (6⋅2) 58 (5⋅0)
Values in parentheses are percentages unless indicated otherwise; *values are median (i.q.r.). Patients were considered to have received a course of
non-steroidal anti-inflammatory drugs (NSAIDs) if received on at least 2 of the first 3 days after surgery. IHD, ischaemic heart disease; PAD, peripheral
artery disease; COPD, chronic obstructive pulmonary disease; ERAS, enhanced recovery after surgery. †χ2 test, except ‡Mann–Whitney U test (§variable
is ordinal).
NSAIDs were significantly less likely to be treated with
strong opioids (35⋅3 versus 56⋅7 per cent; P < 0⋅001), intra-
venous patient-controlled analgesia (25⋅0 versus 41⋅1 per
cent; P < 0⋅001), and wound catheters (3⋅3 versus 5⋅9 per
cent; P < 0⋅001). However, patients in the NSAID group
were significantly more likely to receive prokinetic drugs
(40⋅8 versus 31⋅0 per cent; P < 0⋅001) and to require red
cell transfusion (10⋅8 versus 8⋅6 per cent; P = 0⋅036) after
operation.
Gastrointestinal recovery
A total of 3716 patients (89⋅2 per cent) achieved GI-2
within the first 10 days after surgery. Of the remainder,
189 (4⋅5 per cent) achieved GI-2 after more than 10 days,
232 (5⋅6 per cent) were discharged before day 10 with-
out having achieved GI-2, and 27 (0⋅6 per cent) died
as inpatients before achieving the outcome. Univariable
analyses of the times to GI-2 are shown in Fig. 1. In the
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Table 2 Operative and postoperative treatment factors by non-steroidal anti-inflammatory drug use
NSAID use
No. of patients No Yes P‡
Operative factors
Operative approach 4164 0⋅001
Minimally invasive 1685 (56⋅0) 621 (53⋅9)
Minimally invasive converted to open 254 (8⋅4) 67 (5⋅8)
Open 1072 (35⋅6) 465 (40⋅3)
Resection type 4157 0⋅024
Colonic – right 1109 (36⋅9) 400 (34⋅8)
Colonic – left 653 (21⋅7) 287 (25⋅0)
Rectal 1047 (34⋅8) 408 (35⋅5)
Total colectomy† 198 (6⋅6) 55 (4⋅8)
Formation of new stoma 4164 0⋅104
No 2032 (67⋅5) 817 (70⋅9)
Ileostomy 551 (18⋅3) 193 (16⋅7)
Colostomy 428 (14⋅2) 143 (12⋅4)
CRP measurement
CRP recorded (POD 1–3) 4161 2378 (79⋅0) 785 (68⋅2) <0⋅001
CRP level on POD 1–3 (mg/l)* 3163 118 (67–191) 100 (37–169) <0⋅001§
Treatment on POD 1–10
Strong opioid for >1 day on POD 1–3 4164 1707 (56⋅7) 407 (35⋅3) <0⋅001
Epidural catheter 4163 561 (18⋅6) 201 (17⋅4) 0⋅395
Intravenous patient-controlled analgesia 4163 1237 (41⋅1) 288 (25⋅0) <0⋅001
Wound catheter 4163 179 (5⋅9) 38 (3⋅3) <0⋅001
Chewing gum 4160 152 (5⋅1) 71 (6⋅2) 0⋅166
Prokinetic drugs 4162 932 (31⋅0) 471 (40⋅8) <0⋅001
Red blood cells 4164 260 (8⋅6) 124 (10⋅8) 0⋅036
μ-Opioid antagonists 4163 41 (1⋅4) 23 (2⋅0) 0⋅158
Values in parentheses are percentages unless indicated otherwise; *values are median (i.q.r.). Patients were considered to have received a course of
non-steroidal anti-inflammatory drugs (NSAID) if received on at least 2 of the first 3 days after surgery. †Includes total and subtotal colonic resection.
CRP, C-reactive protein; POD, postoperative day. ‡χ2 test, except §Mann–Whitney U test.
main analysis, the time to GI-2 was significantly shorter
in patients treated with NSAIDs, with a mean of 4⋅6 days
compared with 4⋅8 days in those not receiving NSAIDs
(HR 1⋅08, 95 per cent c.i. 1⋅00 to 1⋅16; P = 0⋅043). Sen-
sitivity analysis returned a similar difference, but this did
not reach significance (mean 4⋅5 versus 4⋅7 days; HR 1⋅06,
0⋅99 to 1⋅14; P = 0⋅088).
Multivariable analysis
Because a range of demographic and treatment factors
differed between the treatment groups, a multivariable
analysis was undertaken to assess whether NSAID use
was independently associated with GI-2 (Tables S3 and S4,
supporting information). The main analysis showed female
sex (P = 0⋅009), insulin-controlled diabetes (P = 0⋅009),
increasing ERAS scores (P = 0⋅003), minimally invasive
operative approach (P < 0⋅001) and the formation of a new
ileostomy (P < 0⋅001) to be associated with a significantly
shorter time to GI-2. Longer times to GI-2 were observed
in patients with a higher CRP level on postoperative days
1–3 (P < 0⋅001), and in those treated with strong opioids
(P < 0⋅001), epidural catheters (P = 0⋅036), intravenous
patient-controlled analgesia (P = 0⋅019), prokinetic drugs
(P = 0⋅009) and red cell transfusion on postoperative days
1–10 (P = 0⋅005). After accounting for these factors, the
use of NSAIDs was not independently associated with
the time to GI-2 (HR 1⋅04, 95 per cent c.i. 0⋅96 to 1⋅12;
P = 0⋅360). The sensitivity analysis yielded consistent
results (HR 1⋅04, 0⋅96 to 1⋅11; P = 0⋅353).
Safety outcomes
On univariable analysis, no significant difference in dura-
tion of hospital stay was observed between patients who
were treated with NSAIDs and those who were not:
median 8 (i.q.r. 6–11) days in both groups (P = 0⋅635)
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Kaplan–Meier estimated cumulative rates of patients being able to tolerate solid food and to pass stool (GI-2 composite outcome) on each postoperative
day: a main analysis with patients censored at discharge or death without achieving GI-2, and b sensitivity analysis in which patients discharged without
GI-2 were treated as achieving the outcome on the day of discharge, with inpatient deaths treated as being censored on postoperative day 11. The points
have been connected using straight lines, rather than the conventional stepped lines to highlight the differences between groups more clearly. Patients were
considered to have received a course of non-steroidal anti-inflammatory drugs (NSAIDs) if received on at least 2 of the first 3 days after surgery. a P = 0⋅043,
b P = 0⋅088 (univariable Cox regression analysis).
Table 3 Safety outcomes within 30 days of surgery by non-steroidal anti-inflammatory drug use
NSAID use
No. of patients No Yes P§
Postoperative duration of hospital stay (days)* † 4156 8 (6–11) 8 (6–11) 0⋅635¶
Anastomotic leak‡ 3628 120 (4⋅6) 56 (5⋅4) 0⋅349
Intra-abdominal collection 4161 194 (6⋅4) 66 (5⋅7) 0⋅431
Pneumonia 4161 146 (4⋅9) 39 (3⋅4) 0⋅043
Acute kidney injury 3710 377 (13⋅8) 139 (14⋅3) 0⋅666
Readmission 4151 265 (8⋅8) 109 (9⋅5) 0⋅506
Complications (Clavien–Dindo grade) 4160 0⋅251¶
0 1370 (45⋅6) 540 (46⋅8)
I–II 1314 (43⋅7) 509 (44⋅1)
III–V 323 (10⋅7) 104 (9⋅0)
Values in parentheses are percentages unless indicated otherwise; *values are median (i.q.r.). †Values truncated at 30 days. ‡Excluding 526 patients with no
anastomosis. §χ2 test, except ¶Mann–Whitney U test (variable is ordinal).
(Table 3). The rate of anastomotic leak was similar in
the NSAID and no-NSAID groups (5⋅4 versus 4⋅6 per
cent respectively; P = 0⋅349); in subgroup analyses, this
difference remained non-significant for each type of
resection (Table S5, supporting information). The rates
of intra-abdominal collection (5⋅7 versus 6⋅4 per cent;
P = 0⋅431), acute kidney injury (14⋅3 versus 13⋅8 per
cent P = 0⋅666) and readmission (9⋅5 versus 8⋅8 per cent;
P = 0⋅506) were similar in both groups, although patients
treated with NSAIDs had a significantly lower rate of
pneumonia (3⋅4 versus 4⋅9 per cent; P = 0⋅043). There was
no significant difference in overall rates of complications
(P = 0⋅251); minor complications occurred in 44⋅1 versus
43⋅7 per cent, and major complications in 9⋅0 versus 10⋅7
per cent, of patients receiving NSAIDs and no NSAIDs
respectively.
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Table 4 Summary of multivariable binary logistic analyses of safety outcomes within 30 days of surgery
Univariable analysis Multivariable analysis
Odds ratio P Odds ratio P
Postoperative hospital stay >8 days 0⋅93 (0⋅81, 1⋅06) 0⋅279 0⋅87 (0⋅75, 1⋅02) 0⋅083
Anastomotic leak* 1⋅17 (0⋅84, 1⋅61) 0⋅357 1⋅14 (0⋅82, 1⋅59) 0⋅424
Intra-abdominal collection 0⋅88 (0⋅66, 1⋅18) 0⋅387 0⋅87 (0⋅65, 1⋅16) 0⋅338
Pneumonia 0⋅69 (0⋅48, 0⋅98) 0⋅040 0⋅72 (0⋅50, 1⋅04) 0⋅077
Acute kidney injury 1⋅05 (0⋅85, 1⋅30) 0⋅648 1⋅04 (0⋅83, 1⋅29) 0⋅755
Readmission 1⋅08 (0⋅86, 1⋅37) 0⋅507 1⋅09 (0⋅86, 1⋅38) 0⋅480
Clavien–Dindo grade III–V complications 0⋅82 (0⋅65, 1⋅04) 0⋅102 0⋅83 (0⋅65, 1⋅04) 0⋅110
Values in parentheses are 95 per cent confidence intervals. Odds ratios are shown for the non-steroidal anti-inflammatory drug (NSAID) group versus
the no-NSAID group. *Excluding 526 patients with no anastomosis. The multivariable models used a backwards stepwise approach to variable selection,
and considered NSAID use alongside all preoperative and perioperative factors from Tables S3 and S4 (supporting information). Full information on the
multivariable models is available in Tables S6–S8 (supporting information).
The analysis was repeated using a multivariable approach,
to account for the potentially confounding effect of other
preoperative and perioperative factors. The results were
consistent with those of the univariable analyses, with
no significant differences in safety outcomes between the
treatment groups (Table 4; Tables S6–S8, supporting infor-
mation). The difference in rates of pneumonia identified
on univariable analysis narrowly missed significance in the
multivariable model, with an odds ratio (OR) of 0⋅72 (95
per cent c.i. 0⋅50 to 1⋅04; P = 0⋅077) for the NSAID versus
no-NSAID group.
Discussion
This large observational study provided validated data on
the safety of NSAIDs after colorectal surgery and their
relationship with gastrointestinal recovery. Their early use
after surgery was not associated with increased rates of
anastomotic leak or acute kidney injury. NSAID use was
not associated with significantly improved gastrointestinal
recovery in multivariable models, but was associated with
a reduced need for strong opioid analgesia after surgery.
The use of NSAIDs after colorectal surgery is contro-
versial. NSAIDs are recommended by enhanced recov-
ery protocols to optimize pain management and to reduce
opioid-related adverse effects7. They may also improve
the recovery of bowel function; a recent meta-analysis8 of
high-quality RCTs demonstrated that NSAIDs reduce the
times to first flatus and stool by 18 and 10 h respectively.
The mechanism for this is unclear, but current evidence
suggests a combination of decreased μ-receptor agonism
and inhibition of COX enzymes, which reduce neuro-
muscular dysfunction6. In contrast, reservations over the
use of NSAIDs are common. NSAIDs may increase the
risk of acute kidney injury, which is common after major
abdominal surgery (14⋅2 per cent), and associated with
excessive 1-year mortality21,22. NSAIDs are also known to
inhibit platelet aggregation, and were associated with a
small increase in red cell transfusion in the present study
(10⋅8 versus 8⋅6 per cent in NSAID and no-NSAID groups
respectively); this was in the absence of excess rates of com-
plications overall. Finally, previous studies10,11 have associ-
ated NSAIDs with increased anastomotic leak after elective
and urgent colorectal resection. In a recent meta-analysis23,
diclofenac was associated with an increased rate of leak (OR
2⋅79, 95 per cent c.i. 1⋅96 to 3⋅96) but ketorolac was not
(OR 1⋅36, 0⋅89 to 2⋅06). This association remains incon-
clusive and has yet to be corroborated in studies with a low
risk of bias.
Fewer patients who received NSAIDs in the present
study required strong opioid analgesia. The prescrip-
tion of opioids after surgery has become a topical issue,
owing to their profile of adverse effects and contribu-
tion to national opioid epidemics24. Many interventions
to reduce opioid use after surgery have been explored,
including use of epidural and wound catheters. Unfor-
tunately, many of these are invasive, are associated with
infective complications, or are restrictive for mobility
and enhanced recovery. Despite the apparent association
between NSAIDs and reduced opioid requirements, only
one-quarter of patients received a relevant dose in the
present study, which is consistent with previous reports19.
This is surprising as NSAIDs are widely recommended by
international enhanced recovery guidelines7. It is possible
that this reflects a lack of equipoise across the colorec-
tal community, influenced by conflicting safety data. Dif-
ferences between international subcommunities cannot be
excluded. Although this study did not consider the role of
specific NSAIDs, it adds to a growing body of data that
support their safety.
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Strengths of the present study are recognized. First, the
definition of ileus is variable and often arbitrary, which
is problematic for performing robust clinical trials and
commissioning new treatments in clinical practice25. A
validated measure of gastrointestinal recovery (GI-2) was
used here, which reduced variation in defining ileus across
a multicentre centre setting16. Second, in recognizing that
some patients are discharged before achieving GI-2 (before
the passage of stool), a prospective sensitivity analysis was
preplanned12. This helped to increase the generalizability
of the study findings across settings, where variable criteria
for hospital discharge may exist. Other strengths of the
study include its delivery across a student- and trainee-led
collaborative network (facilitating a large and real-life
snapshot of clinical practice), a prospective validation
exercise (confirming the quality of data arising from mul-
tiple sources), and the administration of a centre-specific
survey of enhanced recovery (allowing clinically relevant
adjustment of results within statistical models).
The main weakness of the study was its observational
design, with the decision to prescribe NSAIDs being at
the discretion of the clinical team. As such, there is the
potential for selection bias, highlighted by the difference
in patient demographics and postoperative character-
istics between treatment groups. To account for this,
multivariable analyses were used to adjust for poten-
tially confounding factors. However, there are likely to
be other important variables that were not measured or
adjusted for in this study, meaning that residual selection
bias may persist. Another potential weakness was the
statistical power of the analysis. A sample size calculation
determined that a sample of 3500 would be sufficient to
detect a difference in time to GI-2 of 0⋅2 days between
groups. This target was satisfied, but the calculation did
not account for the presence of selection bias, which, after
multivariable adjustment, produced a smaller adjusted
effect of NSAIDs. Despite this, the observed difference
of 0⋅2 days in univariable analysis was small. Even if the
statistical power were increased, the clinical relevance of
such a small effect size would be questionable. Finally, the
use of NSAIDs was considered relevant only if they were
administered in the early postoperative phase (days 1–3).
Although the pathophysiology of anastomotic leak is not
necessarily homogeneous in all settings, this is justified
as the impact of NSAIDs on normal anastomotic healing
(reduced anastomotic COX-2 level) is evident by the third
day after operation in preclinical models26.
Although the present observational data do not support
the efficacy of NSAIDs to reduce ileus after colorectal
surgery, there remains a good case for their use in the
postoperative setting. Previous data relating to the risk of
acute kidney injury are strong and the use of NSAIDs in
this setting must be done according to appropriate patient
selection. Previous data on the risk of anastomotic leak
are inconsistent and not supported by the present findings.
For as long as NSAIDs are endorsed by evidence-based
enhanced recovery guidelines, their use remains justified.
Moving forward, an assessment of equipoise is required to
explore factors that may influence the use of NSAIDs after
colorectal surgery.
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